Skip to content


Evista, Optruma (raloxifene) is a small molecule pharmaceutical. Raloxifene was first approved as Evista on 1997-12-09. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat postmenopausal osteoporosis. The pharmaceutical is active against estrogen receptor and estrogen receptor beta. In addition, it is known to target G-protein coupled estrogen receptor 1 and estrogen receptor beta.
Trade Name Evista, Optruma
Common Name Raloxifene
Indication postmenopausal osteoporosis
Drug Class Antiestrogens of the clomifene and tamoxifen groups
Get full access now